Back
Karyopharm Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
KPTI
Sponsored
I love this overnight trade happening Thursday
Access my free presentation on these overnight trades right here
Buy
54
KPTI
Karyopharm Therapeutics
Last Price:
1.12
Seasonality Move:
-2.24%
7 Day Trial
ALL ACCESS PASS
$
7
This DeFi Coin Could 10x Soon... I Advise You Get In Now!
Discover this DeFi diamond before the next surgeKaryopharm Therapeutics Price Quote
$1.12
-0.01 (2.75%)
(Updated: May 4, 2024 at 6:25 AM ET)
Karyopharm Therapeutics Key Stats
Buy
54
Karyopharm Therapeutics (KPTI)
is a Buy
Day range:
$1.08 - $1.19
52-week range:
$0.62 - $2.91
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.88
P/B ratio:
0%
Volume:
971.9K
Avg. volume:
1.1M
1-year change:
-69.13%
Market cap:
$130M
Revenue:
$146M
EPS:
$-1.25
How Much Does Karyopharm Therapeutics Make?
-
How Much Are Karyopharm Therapeutics's Sales Annually?
KPTI Revenues are $146M -
How Much Profit Does Karyopharm Therapeutics's Make A Year?
KPTI net income is -$143.1M
Is Karyopharm Therapeutics Growing As A Company?
-
What Is Karyopharm Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0% -
What Is Karyopharm Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Karyopharm Therapeutics Stock Price Performance
-
Did Karyopharm Therapeutics Stock Go Up Last Month?
Karyopharm Therapeutics share price went down by -12.06% last month -
Did KPTI's Share Price Rise Over The Last Year?
KPTI share price fell by -69.13% over the past 1 year
What Is Karyopharm Therapeutics 52-Week High & Low?
-
What Is Karyopharm Therapeutics’s 52-Week High Share Price?
Karyopharm Therapeutics has traded as high as $2.91 over the past 52 weeks -
What Is Karyopharm Therapeutics’s 52-Week Low Share Price?
Karyopharm Therapeutics has traded as low as $0.62 over the past 52 weeks
Karyopharm Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Karyopharm Therapeutics?
-
How Much Debt Does Karyopharm Therapeutics Have?
Total long term debt quarterly is $170.9M -
How Much Cash Does Karyopharm Therapeutics Have?
Cash and short term investments quarterly total is $191.4M -
What Is Karyopharm Therapeutics’s Book Value Per Share?
Book value per share is -1.19
Is Karyopharm Therapeutics Cash Flow Positive?
-
What Is KPTI Cash Flow From Operations?
Cash flow from operations (TTM) is -$92.7M -
What Is Karyopharm Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $1.1M -
What Is Karyopharm Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $7.9M
Karyopharm Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
KPTI return on invested capital is -148.18% -
What Is Karyopharm Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -47.95% -
What Is KPTI Return On Equity?
ROE is a measure of profitability and is 0%
Karyopharm Therapeutics Earnings Date & Stock Price
-
What Is Karyopharm Therapeutics's Stock Price Today?
A single share of KPTI can be purchased today for 1.13 -
What Is Karyopharm Therapeutics’s Stock Symbol?
Karyopharm Therapeutics trades on the nasdaq under the ticker symbol: KPTI -
When Is Karyopharm Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Karyopharm Therapeutics is scheduled on May 3, 2024 -
When Is KPTI's next ex-dividend date?
Karyopharm Therapeutics's next ex-dividend date is May 5, 2024 -
How To Buy Karyopharm Therapeutics Stock?
You can buy Karyopharm Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Karyopharm Therapeutics Competitors
-
Who Are Karyopharm Therapeutics's Competitors?
Below is a list of companies who compete with Karyopharm Therapeutics or are related in some way:
Karyopharm Therapeutics Dividend Yield
Data Unavailable
Karyopharm Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -16.24% |
Revenue: | 0.5% | 0.39% |
Analyst Recommendations
Buy Recommendations: | 2 |
---|---|
Hold Recommendations: | 1 |
Sell Recommendations: | 0 |
Price Target: | 5.57 |
Upside from Last Price: | 393.05% |